Key result
Post-translational modifications of cholesterol transporters emerge as key therapeutic targets in atherosclerosis.
Why the study?
Dysregulation of post-translational modifications of cholesterol receptors and transporters disrupts cholesterol transport homeostasis and accelerates atherosclerosis, offering a potential therapeutic target for atherosclerotic cardiovascular disease.
This review highlights how targeting post-translational modifications of cholesterol receptors and transporters holds translational potential for the prevention and treatment of atherosclerotic cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Post-translational modification pathways may identify novel ASCVD targets; hypothesis-generating and requires prospective trials before clinical adoption.
Hypercholesterolemia drives atherosclerotic cardiovascular disease. Cholesterol transport homeostasis is maintained by a network of membrane receptors on enterocytes, hepatocytes and macrophages, including cholesterol receptors NPC1L1, LDLR, CD36, SR-A and LOX-1, cholesterol transporters ABCA1, ABCG1 and ABCG5/ABCG8, and the bifunctional receptor SR-BI. These proteins coordinate intestinal cholesterol absorption, hepatic clearance of circulating cholesterol and its biliary excretion, and prevention of macrophage-derived foam cell formation. Post-translational modifications (PTMs), including ubiquitination, phosphorylation, proteolysis, glycosylation, palmitoylation and S-nitrosylation, critically govern the stability, subcellular localization and functional activity of these receptors. Dysregulation of these PTMs disrupts cholesterol transport homeostasis and accelerates atherosclerosis. This review first outlines the cell-specific expression profiles of these receptors and their coordinated roles in systemic cholesterol transport. It then summarizes PTM dysregulation in atherosclerosis and metabolic diseases. Subsequently, it provides a detailed analysis of how individual PTMs and their crosstalk modulate receptor stability, membrane trafficking, signal transduction, ligand binding, and transporter activity. Finally, we discuss the translational potential of targeting these PTMs for the prevention and treatment of atherosclerotic cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) conducted a review in Atherosclerosis and hypercholesterolemia. Targeting post-translational modifications of cholesterol receptors and transporters was evaluated. Post-translational modifications of cholesterol receptors and transporters critically govern cholesterol transport homeostasis and represent potential therapeutic targets for atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: